Life Expectancy in Duchenne Muscular Dystrophy: Reproduced Individual Patient Data Meta-analysis
- PMID: 34645707
- PMCID: PMC8665435
- DOI: 10.1212/WNL.0000000000012910
Life Expectancy in Duchenne Muscular Dystrophy: Reproduced Individual Patient Data Meta-analysis
Abstract
Background and objectives: Duchenne muscular dystrophy (DMD) is a rare progressive disease that is often diagnosed in early childhood and leads to considerably reduced life expectancy; because of its rarity, research literature and patient numbers are limited. To fully characterize the natural history, it is crucial to obtain appropriate estimates of the life expectancy and mortality rates of patients with DMD.
Methods: A systematic review of the published literature on mortality in DMD up to July 2020 was undertaken, specifically focusing on publications in which Kaplan-Meier (KM) survival curves with age as a timescale were presented. These were digitized, and individual patient data (IPD) were reconstructed. The pooled IPD were analyzed with the KM estimator and parametric survival analysis models. Estimates were also stratified by birth cohort.
Results: Of 1,177 articles identified, 14 publications met the inclusion criteria and provided data on 2,283 patients, of whom 1,049 had died. Median life expectancy was 22.0 years (95% confidence interval [CI] 21.2, 22.4). Analyses stratified by 3 time periods in which patients were born showed markedly increased life expectancy in more recent patient populations; patients born after 1990 have a median life expectancy of 28.1 years (95% CI 25.1, 30.3).
Discussion: This article presents a full overview of mortality across the lifetime of a patient with DMD and highlights recent improvements in survival. In the absence of large-scale prospective cohort studies or trials reporting mortality data for patients with DMD, extraction of IPD from the literature provides a viable alternative to estimating life expectancy for this patient population.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Figures


Similar articles
-
Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis.Eur J Epidemiol. 2020 Jul;35(7):643-653. doi: 10.1007/s10654-020-00613-8. Epub 2020 Feb 27. Eur J Epidemiol. 2020. PMID: 32107739 Free PMC article.
-
Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls.Muscle Nerve. 2024 Jul;70(1):60-70. doi: 10.1002/mus.28075. Epub 2024 Mar 14. Muscle Nerve. 2024. PMID: 38482981
-
Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011.Ann Phys Rehabil Med. 2013 Sep;56(6):443-54. doi: 10.1016/j.rehab.2013.06.002. Epub 2013 Jun 24. Ann Phys Rehabil Med. 2013. PMID: 23876223
-
Natural history of Duchenne muscular dystrophy in the United Kingdom: A descriptive study using the Clinical Practice Research Datalink.Brain Behav. 2023 Dec;13(12):e3331. doi: 10.1002/brb3.3331. Epub 2023 Nov 13. Brain Behav. 2023. PMID: 37957895 Free PMC article.
-
Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis.Orphanet J Rare Dis. 2020 Jun 5;15(1):141. doi: 10.1186/s13023-020-01430-8. Orphanet J Rare Dis. 2020. PMID: 32503598 Free PMC article.
Cited by
-
Current Challenges of Using Patient-Level Claims and Electronic Health Record Data for the Longitudinal Evaluation of Duchenne Muscular Dystrophy Outcomes.Adv Ther. 2024 Sep;41(9):3615-3632. doi: 10.1007/s12325-024-02897-8. Epub 2024 Jul 30. Adv Ther. 2024. PMID: 39080221 Free PMC article.
-
Association of a novel dystrophin (DMD) genetic nonsense variant in a cat with X-linked muscular dystrophy with a mild clinical course.J Vet Intern Med. 2024 Mar-Apr;38(2):1160-1166. doi: 10.1111/jvim.17024. Epub 2024 Feb 28. J Vet Intern Med. 2024. PMID: 38415938 Free PMC article.
-
Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.J Comp Eff Res. 2023 Apr;12(4):e220190. doi: 10.57264/cer-2022-0190. Epub 2023 Feb 7. J Comp Eff Res. 2023. PMID: 36749302 Free PMC article. Clinical Trial.
-
Inhibiting EZH2 complements steroid effects in Duchenne muscular dystrophy.Sci Adv. 2025 Mar 14;11(11):eadr4443. doi: 10.1126/sciadv.adr4443. Epub 2025 Mar 14. Sci Adv. 2025. PMID: 40085707 Free PMC article.
-
Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne Muscular Dystrophy: From FDA-approved drugs to peptide-conjugated ASO.Curr Res Toxicol. 2024 Jun 18;7:100182. doi: 10.1016/j.crtox.2024.100182. eCollection 2024. Curr Res Toxicol. 2024. PMID: 38983605 Free PMC article.
References
-
- San Martin PP, Solis FF, Cavada CG. Survival of patients with Duchenne muscular dystrophy. Revista Chilena de Pediatria. 2018;89(4):477. - PubMed
-
- Mochizuki H, Miyatake S, Suzuki M, et al. . Mental retardation and lifetime events of Duchenne muscular dystrophy in Japan. Intern Med. 2008;47(13):1207-1210. - PubMed
-
- Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12(10):926-929. - PubMed
-
- Bergen JC, Ginjaar HB, Essen AJ, et al. . Forty-five years of Duchenne muscular dystrophy in the Netherlands. J Neuromuscul Dis. 2014;1(1):99-109. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous